Skip to main navigation
Skip to search
Skip to main content
Northwestern Scholars Home
Help & FAQ
Home
Experts
Organizations
Research Output
Grants
Core Facilities
Research Data
Search by expertise, name or affiliation
View Scopus Profile
Shuo Ma
Professor
,
Medicine, Hematology Oncology Division
Member
,
Robert H. Lurie Comprehensive Cancer Center
Email
shuo-ma
northwestern
edu
h-index
h10-index
h5-index
4810
Citations
28
h-index
Calculated based on number of publications stored in Pure and citations from Scopus
2431
Citations
22
h-index
Calculated based on number of publications stored in Pure and citations from Scopus
1007
Citations
15
h-index
Calculated based on number of publications stored in Pure and citations from Scopus
1999 …
2025
Research activity per year
Overview
Fingerprint
Network
Grants
(40)
Research Output
(76)
Similar Profiles
(6)
Fingerprint
Dive into the research topics where Shuo Ma is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Chronic Lymphocytic Leukemia
100%
Relapsed or Refractory
32%
Ibrutinib
27%
Rituximab
23%
Venetoclax
23%
Bruton Tyrosine Kinase Inhibitor
19%
Relapsed or Refractory Acute Myeloid Leukemia
16%
Progression-free Survival
14%
Pirtobrutinib
14%
Chimeric Antigen Receptor T-cell Therapy
13%
B-cell Malignancies
12%
Marginal Zone Lymphoma
11%
Targeted Therapy
11%
Minimal Residual Disease
11%
Chemoimmunotherapy
11%
Leukocytes
10%
Idelalisib
10%
Waldenström Macroglobulinemia
10%
Overall Response Rate
10%
Adverse Events
9%
Alemtuzumab
9%
Complete Response
9%
Treatment Options
8%
Confidence Interval
8%
Non-covalent
8%
Small Lymphocytic Lymphoma
8%
Chronic Lymphocytic Leukemia Cells
8%
Phase II Study
8%
Duration of Response
8%
Frontline Treatment
8%
Median Progression-free Survival
8%
Therapeutic Monoclonal Antibody
8%
Endothelial Cells
8%
Monotherapy
7%
Highly Selective
7%
Phase II Trial
7%
Oncology
7%
Risk Factors
7%
BTK Inhibitor
7%
Clinical Outcomes
7%
Overall Survival
7%
NCCN Guidelines
7%
Mantle Cell Lymphoma
7%
Previously Untreated
7%
Dictyostelium
6%
Rituximab-refractory
6%
Single Center
6%
COVID-19 Vaccination
6%
Frontline Therapy
6%
Chemoresistance
6%
Medicine and Dentistry
B-Cell Chronic Lymphocytic Leukemia
91%
Lymphocytic Lymphoma
44%
Progression Free Survival
24%
Ibrutinib
23%
Rituximab
22%
B Cell
21%
Bruton Tyrosine Kinase Inhibitor
19%
Venetoclax
19%
Adverse Event
17%
Non-Hodgkin Lymphoma
16%
Overall Survival
15%
Diseases
15%
Chimeric Antigen Receptor T-Cell Immunotherapy
13%
Minimal Residual Disease
12%
MALT Lymphoma
11%
Malignant Neoplasm
11%
Chronic Lymphocytic Leukemia
10%
Waldenström's Macroglobulinemia
10%
Cancer
10%
Chemoimmunotherapy
9%
B-Cell Lymphoma
8%
Monotherapy
8%
Targeted Therapy
8%
Oncology
8%
Survival Rate
8%
Drug Resistance
7%
Chemotherapy
7%
Mantle Cell Lymphoma
7%
Leukocyte
6%
RNA Processing
6%
COVID-19 Vaccination
6%
Observational Study
6%
Humoral Immunity
6%
Treatment Duration
6%
Infection
6%
Atrial Fibrillation
5%
Lymphoma
5%
Alternative RNA Splicing
5%
Pharmacology, Toxicology and Pharmaceutical Science
Chronic Lymphatic Leukemia
93%
Rituximab
29%
Lymphocytic Lymphoma
29%
Venetoclax
22%
Ibrutinib
20%
Progression Free Survival
19%
Adverse Event
16%
Disease
16%
Minimal Residual Disease
15%
Bruton Tyrosine Kinase Inhibitor
15%
Malignant Neoplasm
11%
Nonhodgkin Lymphoma
11%
Chemotherapy
10%
Idelalisib
10%
Overall Survival
10%
Monotherapy
8%
Drug Resistance
7%
Chimeric Antigen Receptor
7%
Marginal Zone Lymphoma
6%
Waldenstroem macroglobulinemia
6%
Alemtuzumab
6%
Mantle Cell Lymphoma
6%
Remission
6%
Survival Rate
6%
Immunotherapy
5%
Lymphoma
5%
Bruton Tyrosine Kinase
5%
B Lymphocyte Receptor
5%
Neutropenia
5%